Highlights

  • Second quarter 2026 revenue was $28,097 thousand, compared with $21,199 thousand, and net loss was $19,268 thousand.
  • Product revenue was $21,241 thousand and subscription revenue was $6,856 thousand for the quarter ended June 30, 2026.
  • Cash, cash equivalents and marketable securities were $129.3 million and the accumulated deficit was $259.4 million at June 30.
  • Management expects 2026 total revenue of $114 million to $117 million, versus prior guidance of $112 million to $116 million.

CeriBell, Inc. (NASDAQ: CBLL) shares were trading at USD 27.03 on October 27, 2026, with a relative volume at time of 2.56. The medical technology company received a new FDA 510(k) clearance in June 2026, entered into a Credit Agreement with MidCap Funding IV Trust on August 5, 2026, and reported second quarter 2026 results on August 10, 2026, with raised full-year revenue guidance.

CeriBell is incorporated in Delaware and has principal executive offices at 360 N. Pastoria Avenue in Sunnyvale, California. It develops the Ceribell System, a point-of-care electroencephalography (EEG) platform that combines portable hardware, with AI-powered algorithms for detecting and monitoring seizures and delirium in acute care settings. The filing states that, as of June 30, 2026, the system had been deployed to more than 700 hospitals. Its fiscal year ends December 31.

Second Quarter 2026 Results

The Form 10-Q covers the quarter ended June 30, 2026 and reports unaudited results. Total revenue was $28,097 thousand, compared with $21,199 thousand for the second quarter of 2025. Product revenue was $21,241 thousand, compared with $15,923 thousand, and subscription revenue was $6,856 thousand, compared with $5,276 thousand.

Gross profit was $25,938 thousand, compared with $18,682 thousand. Operating expenses were $45,919 thousand, compared with $33,634 thousand, including sales and marketing of $24,415 thousand.

The loss from operations was $19,981 thousand and the net loss was $19,268 thousand, or $0.51 per share, compared with a net loss of $13,643 thousand, or $0.38 per share. For the six months, revenue was $54,591 thousand and the net loss was $39.0 million, or $1.03 per share, compared with $0.73 per share.

Balance Sheet, Debt and Cash Flow

As of June 30, 2026, CeriBell had $129.3 million in cash, cash equivalents and marketable securities and $20.0 million of term loans. Net cash used in operating activities was $32,160 thousand for the six months ended June 30, 2026, compared with $18,936 thousand a year earlier. The company expects to continue to incur losses.

The company stated that it believes its cash, cash equivalents and marketable securities, together with expected cash generated from revenue, will be sufficient to fund planned operating expenses and capital expenditures for at least the next 12 months. It added that it could deplete capital sooner than expected and may need to raise additional capital.

On August 5, 2026, CeriBell entered into a Credit Agreement providing a term loan facility with a $30.0 million commitment and $25.0 million of uncommitted capital, and a revolving facility of up to $20.0 million. At closing the company borrowed $20.0 million under the revolving facility.

Litigation and Management Commentary

CeriBell filed patent infringement complaints against Natus Medical Incorporated and related subsidiaries with the U.S. International Trade Commission and the U.S. District Court for the District of Delaware in July 2025. As of June 30, 2026, the company has a commitment to pay $2.9 million in deferred legal fees contingent on the earlier of settlement or an Initial Determination by the Administrative Law Judge in the company's favor. No accrual has been recorded.

On the call, management said 712 hospitals were active accounts at quarter end and that operating expenses included $3.9 million of intellectual property litigation costs. It said a New Technology Add-On Payment of up to $2,170 per qualified patient for delirium monitoring takes effect October 1, 2026, with a full commercial launch planned for the fourth quarter of 2026.

2026 Outlook

Management said it expects full-year 2026 total revenue of $114 million to $117 million, up from prior guidance of $112 million to $116 million. It said the range does not include material contributions from its neonate, pediatric or delirium products, which it expects to begin translating into revenue more meaningfully in 2027.